To include your compound in the COVID-19 Resource Center, submit it here.

NovaBay's NVC-422 misses Phase II endpoint

NovaBay Pharmaceuticals Inc. (NYSE-A:NBY) said NVC-422 ophthalmic solution missed the primary endpoint

Read the full 124 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE